NCI-CCC Lymphoma Tumor Board Question

Questions discussed in this category

How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?

4 Answers available

How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?

240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...

2 Answers available

How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?

Would your approach differ for a 30 year old and a 70 year old?

3 Answers available

What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...

1 Answer available

In light of the TRIANGLE data at ASH, how are you now approaching a transplant-eligible patient with a new Dx of agressive mantle cell lymphoma?

Are you adding ibrutinib? Should we add ibrutinib to NORDIC? Still referring to transplant?

2 Answers available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?

Would you still go to auto or consider allo?

1 Answer available

How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?

Would you intercalate HD-MTX with her CHOEP?

1 Answer available

How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?

2 Answers available

What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?

2 Answers available

How would you manage relapsed DLBCL in a patient who received second line CD19 CART treatment?

1 Answer available

How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?

2 Answers available

How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?

1 Answer available

What treatment would you recommend in an older patient with multiply relapsed double-hit lymphoma with recurrence following ASCT, pola-BR, and CAR-T therapy?

1 Answer available

How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?

1 Answer available

Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?

2 Answers available

What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?

1 Answer available

How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?

1 Answer available

In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?

1 Answer available

How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?

1 Answer available

How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?

1 Answer available

How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?

Would you give R-CHOP without knowing if there was use of prior anthracycline?

1 Answer available

How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?

Ki67 = 90% with multiple small nodes on PET scan and normal CBC

1 Answer available

How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?

2 Answers available

What's the optimal management of stage IA nodal ATLL in a young fit patient?

Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...

1 Answer available

Papers discussed in this category

Eur J Haematol, 2023 Mar 27

Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.

Haematologica, 2021 Jun 01

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Outcome of deferred initial therapy in mantle-cell lymphoma.

The New England journal of medicine, 2015-11-05

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Haematologica, 2018 May 24

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.

Blood,

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.

Leukemia, 2011 Jul 01

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.

Haematologica, 2019 Sep 19

mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Blood, 2017 Aug 17

mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Blood, 2015 May 28

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

British journal of haematology, 2017-11

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

J Clin Oncol, 2016 Feb 29

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Lancet Haematol, 2016 Dec 05

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Lancet Oncol, 2022 Jan 21

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

N Engl J Med,

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Lancet (London, England), 2019-01-19

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.

Ann Oncol, 2009 Jul 01

High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood, 2010 Jul 21

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

N Engl J Med, 2022 Jun 03

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

J Hematol Oncol, 2021 Oct 30

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Blood, 2022 Mar 03

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Lancet,

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

N Engl J Med, 2021 Dec 11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Cancer cell, 2017-06-12

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

J Neurooncol, 2022 Jun 20

Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.

Lancet Oncol, 2020 Jun 05

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Lancet Oncol, 2022 Jul 12

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

Related Topics